ALK-Abelló A/S (ALK-B)
Nasdaq Copenhagen · Denmark · prices in DKK · close of 27 Oct 2026
Key indicators
| Last close | DKK 243.40 |
|---|---|
| 52-week range | 191.80 – 271.40 |
| Return, 1 month / 3 months | +21.9% / +7.9% |
| Return, 1 year / 3 years | +14.1% / +214.4% |
| Trend | Uptrend |
| RSI (14) | 73 |
| Volatility (1 year) | 28.0% |
| Worst drawdown (1 year) | -28.9% |
| Average daily value traded | 49.97M DKK |
| Dividend yield | 0.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
ALK-Abello is a Danish pharmaceutical company based near Copenhagen that focuses on allergy treatment. It develops and makes immunotherapy products, including tablets and injections that help people with allergic conditions such as hay fever, allergic asthma and reactions to insect stings. Its customers are mainly doctors, allergy specialists and patients in Europe and North America, and the company also supplies allergy diagnostics and emergency treatments for severe allergic reactions.
The shares are listed on the Nasdaq Copenhagen in Denmark under the code ALK-B, and the price on this page is in Danish kroner (DKK). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
ALK-Abelló A/S (ALK-B) trades on the Nasdaq Copenhagen in Denmark. It last closed at DKK 243.40 on 27 October 2026.
Its price-based Market X-Ray is 52 out of 100 (a fair price profile), ranking 83 of 164 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 14.1% and over the last three months it rose 7.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Copenhagen
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 7.9% | ||
| From 52-week high | -10.0% | ||
| Momentum | 56 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 7.9% | ||
| 6-month return | 6.2% | ||
| 12-month return, skipping the last month | -6.4% | ||
| Stability (higher is calmer) | 49 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 28.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -28.9% | ||
| Liquidity | 84 · Strong | Trades actively. | |
| Average daily value traded | 49.97M DKK | ||
| Zero-volume days | 0.0% | ||
| Income | 6 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.7% | ||
| Years with dividends | 1 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.4% |
|---|---|
| 1 month | +21.9% |
| 3 months | +7.9% |
| 6 months | +6.2% |
| 1 year | +14.1% |
| 3 years | +214.4% |
| 5 years | +78.8% |
Signals
| 50-day / 200-day average | 212.70 / 225.65 |
|---|---|
| Golden / death cross (60 days) | Death, 38 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 5.66 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 17 Mar 2026 | DKK 1.6000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Copenhagen; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.